Current:Home > NewsFDA pulls the only approved drug for preventing premature birth off the market -FundGuru
FDA pulls the only approved drug for preventing premature birth off the market
View
Date:2025-04-15 20:47:40
The Food and Drug Administration is pulling its approval for a controversial drug that was intended to prevent premature births, but that studies showed wasn't effective.
Following years of back-and-forth between the agency and the drugmaker Covis Pharma, the FDA's decision came suddenly Thursday. It means the medication, Makena, and its generics are no longer approved drug products and can no longer "lawfully be distributed in interstate commerce," according to an agency statement.
"It is tragic that the scientific research and medical communities have not yet found a treatment shown to be effective in preventing preterm birth and improving neonatal outcomes," FDA Commissioner Robert M. Califf said in a statement on Thursday.
Hundreds of thousands of babies are born preterm every year in the U.S. It's one of the leading causes of infant deaths, according to a report released by the March of Dimes last year. And preterm birth rates are highest for Black infants compared to other racial and ethnic groups. There is no other approved treatment for preventing preterm birth.
Last month, Covis said it would pull Makena voluntarily, but it wanted that process to wind down over several months. On Thursday, the FDA rejected that proposal.
Makena was granted what's known as accelerated approval in 2011. Under accelerated approval, drugs can get on the market faster because their approvals are based on early data. But there's a catch: drugmakers need to do follow-up studies to confirm those drugs really work.
The results of studies later done on Makena were disappointing, so in 2020 the FDA recommended withdrawing the drug. But because Covis didn't voluntarily remove the drug at the time, a hearing was held in October – two years later – to discuss its potential withdrawal.
Ultimately, a panel of outside experts voted 14-1 to take the drug off the market.
But the FDA commissioner still needed to make a final decision.
In their decision to pull the drug immediately, Califf and chief scientist Namandjé Bumpus quoted one of the agency's advisors, Dr. Anjali Kaimal, an obstetrics and gynecology professor at the University of South Florida.
Kaimal said there should be another trial to test the drug's efficacy, but in the meantime, it doesn't make sense to give patients a medicine that doesn't appear to work: "Faced with that powerless feeling, is false hope really any hope at all?"
veryGood! (61)
Related
- As Trump Enters Office, a Ripe Oil and Gas Target Appears: An Alabama National Forest
- ParkMobile $32.8 million settlement: How to join class
- Sabrina Carpenter Shares Her Self
- Sabrina Carpenter Shares Her Self
- Intellectuals vs. The Internet
- The Voice Season 26 Crowns a New Winner
- Our 12 favorites moments of 2024
- I loved to hate pop music, until Chappell Roan dragged me back
- Small twin
- KISS OF LIFE reflects on sold
Ranking
- Tom Holland's New Venture Revealed
- North Dakota regulators consider underground carbon dioxide storage permits for Midwest pipeline
- 'September 5' depicts shocking day when terrorism arrived at the Olympics
- Atmospheric river and potential bomb cyclone bring chaotic winter weather to East Coast
- Highlights from Trump’s interview with Time magazine
- Taxpayers could get $500 'inflation refund' checks under New York proposal: What to know
- Turning dusty attic treasures into cash can yield millions for some and disappointment for others
- China's ruling Communist Party expels former chief of sports body
Recommendation
Intel's stock did something it hasn't done since 2022
Sabrina Carpenter Shares Her Self
New Jersey targets plastic packaging that fills landfills and pollutes
Travis Kelce Praises Taylor Swift For Making Eras Tour "Best In The World"
Warm inflation data keep S&P 500, Dow, Nasdaq under wraps before Fed meeting next week
Secretly recorded videos are backbone of corruption trial for longest
Sabrina Carpenter reveals her own hits made it on her personal Spotify Wrapped list
Supreme Court allows investors’ class action to proceed against microchip company Nvidia